Catalyst Biosciences Announces Closing of Public Offering of Common Stock
The gross proceeds to the Company from this offering were approximately $34.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company.
- The gross proceeds to the Company from this offering were approximately $34.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company.
- Raymond James & Associates, Inc. acted as the sole book-running manager and JonesTrading Institutional Services LLC,Chardan and LifeSci Capital LLC acted as co-managers for the offering.
- 333-228970) relating to the public offering of the shares of common stock described above was previously filed with and declared effective by the Securities and Exchange Commission (SEC) on February 14, 2019.
- Catalyst is a clinical-stage biopharmaceutical company which is focused on addressing unmet needs in rare diseases and systemic complement mediated disorders.